---
document_datetime: 2023-09-21 18:49:09
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/steps-after-cutoff/vistide-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
document_name: vistide-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
version: success
processing_time: 1.1322199
conversion_datetime: 2025-12-14 20:44:20.817456
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORISATION

For procedures finalised after 30 July 2005 please refer to module 8B.

- On 21 July 1997 the CPMP issued a notification to the Commission relating to changes in the Package  Leaflet  not  connected  to  the  Summary  of  Product  Characteristics.  The  European Commission amended the Decision on 18 March 1997.
- On 13 August 1997 the CPMP issued a notification to the Commission relating to changes in the  labelling  text  of  the  immediate  packaging  in  all  11  languages  in  order  to  have  three combined languages on the Belgian label. The European Commission amended the Decision on 5 November 1997.

· The  CPMP  issued  on  13  August  1997  a  positive  opinion  for  the  transfer  of  the  Marketing Authorisation for Vistide to Pharmacia &amp; Upjohn SA, Luxembourg. The CPMP opinion with its revised  Annexes  was  forwarded,  in  all  official  languages  of  the  European  Union,  to  the European Commission which adopted the Decision on 17 October 1997. · On 4 March 1998 the Marketing Authorisation Holder notified the EMEA of its intention to introduce changes in the Package  Leaflet not connected to the  Summary  of  Product Characteristics. On 14 April 1998 the EMEA has notified the European Commission that the changes were accepted. The European Commission amended the Decision on 2 June 1998 . · On 27 May 1998 the Marketing Authorisation Holder submitted to the EMEA an application for a Type I variation relating to a change in the content of the manufacturing authorisation. On 1 July 1998 the EMEA notified the European Commission that the changes were accepted. This variation did not require any amendments to the Commission Decision . · On  27  May  1998  the  Marketing  Authorisation  Holder  submitted  to  the  EMEA  another application for a Type I variation relating to an extension of the shelf-life. On 1 July 1998 the EMEA has notified the European Commission that the changes were accepted. The European Commission amended the Decision on 18 September 1998 . · On 25 August 1998 the Marketing Authorisation Holder submitted to the EMEA an application for a Type II variation relating to an update of the SPC and the Package Leaflet concerning the inclusion  of  a  statement  regarding  the  potential  for  iritis/uveitis  associated  with  Vistide.  On 19 November 1998 the CPMP issued a positive opinion. The European Commission amended the Decision on 26 February 1999. · On  18  December  1998  the  Marketing  Authorisation  Holder  applied  for  an  update  of  the Summary of Product Characteristics and the relevant sections of the Package Leaflet concerning the inclusion of new information regarding nephrotoxicity. On 25 March 1999 the CPMP issued a positive opinion. The European Commission amended the Decision on 17 June 1999. · On 18 January 2000 the Marketing Authorisation Holder submitted to the EMEA an application for  a  Type  II  (09)  variation  relating  to  an  update  of  section  4.8  of  the  SPC  and  the  relevant section  of  the  Package  Leaflet  following  the  CPMP  Assessment  of  the  3 rd and  4 th Periodic Safety Update Reports. On 12 April 2000 the CPMP issued a positive opinion. The European Commission amended the Decision on 13 July 2000. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below:

| Scope                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Application number   | Type of modification 1   | Notification/ Opinion issued on 2   | Commission Decision Issued/amended on   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|--------------------------|-------------------------------------|-----------------------------------------|
| Change following modification(s) of the manufacturing authorisation(s)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | I/0010               | I                        | 01.10.01                            | 19.02.02                                |
| Change in the name and/or address of the marketing authorisation holder                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | I/0011               | I                        | 01.10.01                            | 19.02.02                                |
| Change in or addition of manufacturer(s) of active substance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | I/0012               | I                        | 09.11.01                            | 19.11.01                                |
| 5 year renewal of the Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | R/0013               | R                        | 23.04.02                            | 10.07.02                                |
| To update the Summary of Product Characteristics (SPC) section 4.8 ('Undesirable Effects') to reflect the frequencies of the adverse drug reactions in accordance with the SPC guideline. The frequencies of nephrotoxic effects are presented according to results in clinical trials. In section 6.6 ('Instructions for handling and disposal'), reference is made to contact the local representative for information in case of difficulty in obtaining probenecid. Relevant changes are also introduced in the Package Leaflet (PL). Moreover, the list of local representatives in the PL has been revised and some editorial changes have been made to the Danish, French and Portuguese translations. Change in the name and/or address of the | II/0014              | II                       | 18.12.02                            | 17.03.03                                |
| marketing authorisation holder Change in the name and/or address of a manufacturer of the finished product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | I/0015               | I                        | 27.09.04 authorised                 | 24.06.05                                |

1 In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: I refers to a minor variation (Type I variation); II refers to a major variation (Type II variation); I/II refers to a minor variation following the procedure set out in Article 6, 7 and 8 of the Regulation; X refers to an Annex II application.

## To update the Summary of Product Characteristics (SPC) section 4.8 ('Undesirable Effects') to reflect the frequencies of the adverse drug reactions in accordance with the SPC guideline. The frequencies of nephrotoxic effects are presented according to results in clinical trials. In section 6.6 ('Instructions for handling and disposal'), reference is made to contact the local representative for information in case of difficulty in obtaining probenecid. Relevant changes are also introduced in the Package Leaflet (PL). Moreover, the list of local representatives in the PL has been revised and some editorial changes have been made to the Danish, French and Portuguese translations. Change in the name and/or address of the marketing authorisation holder Change in the name and/or address of a manufacturer of the finished product Medicinal product no longer authorised

T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 of 7 November 1996.

N refers  to  a  notification  in  accordance  with  Article  10(3)  of  Council  Directive  92/27/EEC  of  31 March 1992.

2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification date. The Commission Decision will be amended accordingly.